Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome

Am J Hematol. 2019 Dec;94(12):E322-E325. doi: 10.1002/ajh.25630. Epub 2019 Oct 2.

Authors

Sanfang Tu¹, Rui Huang¹, Zhenling Guo¹, Lan Deng¹, Chaoyang Song¹, Xuan Zhou¹, Chunyan Yue¹, Lenghe Zhang¹, Yanjie He¹, Jilong Yang¹, Zhao Liang¹, Jingwen Du¹, Peihua Cao², Yushen Li³, Lung-Ji Chang^{3

4

5}, Yuhua Li¹

Affiliations

¹ Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
² Department of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
³ Department of research and development, Geno-Immue Medical Institute, Shenzhen, China.
⁴ School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
⁵ Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida.

PMID: 31489688
DOI: 10.1002/ajh.25630

No abstract available

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Antigens, CD19 / immunology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Brain Diseases / etiology
Brain Diseases / prevention & control*
Cell Culture Techniques*
Cells, Cultured
Combined Modality Therapy
Cytokine Release Syndrome / etiology
Cytokine Release Syndrome / prevention & control*
Disease-Free Survival
Dose-Response Relationship, Immunologic
Female
Follow-Up Studies
Humans
Immunotherapy, Adoptive* / adverse effects
Kaplan-Meier Estimate
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
T-Cell Antigen Receptor Specificity
Time Factors
Tumor Burden
Young Adult

Substances

Antigens, CD19
CD19 molecule, human

Grants and funding